Kimia biosciences Limited has secured a significant patent grant from The Patent Office, Government of India, strengthening its position in the antifungal pharmaceutical segment. The company announced this development through a regulatory filing to BSE Limited on February 10, 2026, pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Patent Details and Specifications

The patent, officially numbered 579384, covers an "Improved Process for the Preparation of Luliconazole," an important antifungal active pharmaceutical ingredient (API). The patent certificate confirms the grant for a standard term of 20 years, effective from the original filing date.

Strategic Impact on Business Portfolio

The patent grant represents a significant addition to Kimia Biosciences' intellectual property portfolio, particularly in the antifungal API segment. According to the company's regulatory communication, this patent is expected to enhance long-term business prospects by providing exclusive rights to the improved manufacturing process for Luliconazole.

Luliconazole is a topical antifungal medication used to treat various fungal skin infections. The patent covers an improved preparation process, which could potentially offer manufacturing advantages such as enhanced efficiency, better yield, or improved product quality compared to existing methods.

Regulatory Compliance and Documentation

The announcement was made through proper regulatory channels, with Company Secretary and Compliance Officer Pallavi Garg (Membership No. A69848) signing the disclosure document. The filing includes the complete patent certificate as supporting documentation, ensuring full transparency with stakeholders and regulatory authorities.

Patent Maintenance Requirements

The patent certificate specifies that renewal fees for maintaining the patent will be due on January 9, 2024, and annually thereafter on the same date. This ongoing financial commitment will be necessary to preserve the exclusive rights throughout the 20-year patent term.

This patent grant positions Kimia Biosciences Limited to potentially leverage its proprietary process technology in the competitive antifungal API market, providing a foundation for future business development and market expansion opportunities.

Kimia biosciences Limited has announced a significant leadership change with the resignation of its Chief Financial Officer (CFO) Mr. Naveen Sharma, effective February 2, 2026. The pharmaceutical company communicated this development to BSE Limited under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Resignation Details

Mr. Naveen Sharma tendered his resignation from the position of CFO and key managerial personnel on February 2, 2026, citing personal reasons for his departure. He will be relieved from his responsibilities with the close of business hours on the same date.

Regulatory Compliance

The company has fulfilled all mandatory disclosure requirements under SEBI regulations. Company Secretary and Compliance Officer Pallavi Garg (Membership No. A69848) signed the official intimation letter, ensuring compliance with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024.

The resignation letter was formally submitted through email communication from Mr. Sharma to the company management, requesting proper filing with the Registrar of Companies (ROC) and appropriate intimation to stock exchanges as per regulatory framework.

Company Information

Kimia Biosciences Limited operates from its registered office at Village Bhondsi, Damdama Lake Road, Gurugram, Haryana, with corporate office located in New Delhi. The company trades on BSE under scrip code 530313 with the symbol KIMIABL.

Documentation

All required annexures and supporting documents have been submitted to the stock exchange, including detailed particulars of the cessation as mandated by SEBI listing regulations. The company has maintained transparency in its disclosure process throughout this leadership transition.